February 01, 2021
1 min read
Save
FDA grants fast track designation to GLR2007 for glioblastoma
The FDA granted fast track designation to GLR2007 for treatment of glioblastoma, according to the agent’s manufacturer.
GLR2007 (Gan & Lee Pharmaceuticals) is a cyclin-dependent kinase 4/6 inhibitor in development for treatment of advanced solid tumors.
Glioblastoma is the most common brain and central nervous system malignancy, accounting for approximately 45% of primary tumors. More than 80% of patients die within 2 years of diagnosis, and nearly 95% die within 5 years.
“The poor prognosis and low survival rates for glioblastomas demonstrate an unmet need for new treatment options,” Julius Huang, PhD, DABT, director of global clinical sciences with Gan & Lee, said in a company-issued press release.
Published by:
Read more about